Sequenom Signs Supply Deal for T21 Test with Illumina; Firms to Collaborate on Regulatory Approval | GenomeWeb

Sequenom has signed a supply agreement with Illumina related to its noninvasive sequencing-based trisomy 21 test and will collaborate with the instrument vendor to submit an in vitro diagnostic test for approval.

Under the three-year supply agreement for Illumina's HiSeq 2000 platform, Sequenom and its subsidiaries will purchase sequencing equipment and consumables for use in the development of the Down syndrome test, which detects an overabundance of chromosome 21 in pregnant women.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.